THE-OPEN-GROUP
25.4.2022 14:02:17 CEST | Business Wire | Press release
The Open Group, the vendor-neutral technology consortium, today announced the release of the TOGAF® Standard, 10th Edition, marking a major milestone in the development of the world’s most widely-used Enterprise Architecture framework. Developed by The Open Group Architecture Forum, today’s release introduces a refreshed modular structure which will make it easier to apply the TOGAF framework to different kinds of organizations and styles of architecture.
Building on over twenty-five years of development and constant input from the forum’s global community of EA thought leaders, the TOGAF® Standard, 10th Edition expands the material available to architecture practitioners to make adoption of best practices easier. With greatly expanded guidance and “how-to” material, it enables organizations to operate in an efficient and effective way across a broad range of use-cases, including Agile enterprises and Digital Transformation.
The modular structure provides Enterprise Architects with greater guidance, and simpler navigation, for applying the TOGAF framework alongside its comprehensive fundamental knowledge base. By framing the knowledge base and the topic-specific guidance as separate, formal parts of the TOGAF Standard, the new release will also make it possible to release additional material more frequently while maintaining continuity and stability in its fundamental content.
“The Open Group shares a collective vision of Boundaryless Information Flow™, and the release of the TOGAF® Standard, 10th Edition is a powerful expression of that vision”, commented Steve Nunn, CEO and President of The Open Group. “The next decade of technology and business pressures will require organizations to be more agile, resilient, and adaptable than ever, and that will make a clear approach to architecture more important than ever. I am proud of what The Open Group Architecture Forum has produced for this release, which makes the TOGAF framework significantly more usable by even more businesses while maintaining its core values of consistency, openness, and efficiency.”
“The TOGAF Standard, 10th Edition shows you where to find enduring and universal concepts. It highlights where to find stable, proven best practice. It underscores where to look for new emerging ideas. Bringing together universal concepts, best practice guidance, and emerging ideas is how you adapt the TOGAF Standard for your configured Enterprise Architecture practice,” commented Chris Forde, VP Enterprise Architecture of The Open Group.
The TOGAF® Standard, 10th Edition continues to grow the framework’s ability to enable fundamental aspects of business strategy. These enhancements will also benefit vendors in terms of their ability to deliver competitive new features and services to customers in specialized market segments while adhering to open standards which underpin interoperability.
“The fact that the TOGAF Standard is a living body of knowledge is one of its great advantages,” continued Steve Nunn. “We have now arrived at a point where business strategy and digital solutions are inseparable, and organizations of every size, in every sector, face the need to establish Agile ways of working which continually evolve and adapt. The TOGAF® Standard, 10th Edition shows how the TOGAF ecosystem is itself adapting to this reality, growing with businesses to deliver significant value in times of change.”
- ENDS -
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 870 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
